Cold chain transportation decision in the vaccine supply chain

Qi, Lin; Zhao, Qiuhong; Lev, Benjamin

doi:10.1016/j.ejor.2019.11.005

Cited by 124 publications

(64 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, intramuscular vaccinations are typically given by professional healthcare service providers in the United States, but trained medical personnel are not as available in many countries. Access to vaccines heavily depends on their formulations which are often delicate and require storage in coolers or cryotanks, presenting challenges in transportation and cold-chain distribution [ 243 ]. An oral adenovirus based-vaccine for SARS-CoV-2 S protein has been developed in response to these challenges, offering advantages of utilizing mucosal immunity with ease of storage and needle-free applications [ 244 ].…”

Section: Covid-19 Vaccinesmentioning

confidence: 99%

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung

Thone

Kwon

2021

Advanced Drug Delivery Reviews

308

265

View full text Add to dashboard Cite

Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech’s mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease.

show abstract

Section: Covid-19 Vaccinesmentioning

confidence: 99%

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung

Thone

Kwon

2021

Advanced Drug Delivery Reviews

308

265

View full text Add to dashboard Cite

show abstract

“… Dai et al (2016) provide a contract to incentivize at-risk early production and eliminate double marginalization. Lin et al (2020) also study a two-echelon vaccine supply chain consisting a distributor and a retailer (hospital or clinic) and study the choice between a cold chain or non-cold chain to transport the vaccines.…”

Section: Literature Reviewmentioning

confidence: 99%

Implications of government subsidy on the vaccine product R&D when the buyer is risk averse

Xie

Hou

Han

2021

Transportation Research Part E: Logistics and Transportation Re

View full text Add to dashboard Cite

show abstract

“…Vaccines are highly sensitive to temperature, and their transportation at unfavorable temperatures significantly affects their quality. Lin et al [20] developed a vaccine transportation model by utilizing a cold supply chain network. Their model analyzed how the inspection policy of the retailer influences the distributor’s decision.…”

Section: Introductionmentioning

confidence: 99%